

# CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by *MPL* mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

Manuela Germeshausen and Matthias Ballmaier

Central Research Facility Cell Sorting, Hannover Medical School, Hannover, Germany



## ABSTRACT

Congenital amegakaryocytic thrombocytopenia caused by deleterious homozygous or compound heterozygous mutations in *MPL* (CAMT-MPL) is a rare inherited bone marrow failure syndrome presenting as an isolated thrombocytopenia at birth progressing to pancytopenia due to exhaustion of hematopoietic progenitors. The analysis of samples and clinical data from a large cohort of 56 patients with CAMT-MPL resulted in a detailed description of the clinical picture and reliable genotype-phenotype correlations for this rare disease. We extended the spectrum of CAMT causing *MPL* mutations regarding number (17 novel mutations) and impact. Clinical courses showed great variability with respect to the severity of thrombocytopenia, the development of pancytopenia and the consequences from bleedings. The most severe clinical problems were (i) intracranial bleedings pre- and perinatally and the resulting long-term consequences, and (ii) the development of aplastic anemia in the later course of the disease. An important and new finding was that thrombocytopenia was not detected at birth in a quarter of the patients. The rate of non-hematological abnormalities in CAMT-MPL was higher than described so far. Most of the anomalies were related to the head region (brain anomalies, ocular and orbital anomalies) and consequences of intracranial bleedings. The present study demonstrates a higher variability of clinical courses than described so far and has important implications on diagnosis and therapy. The diagnosis CAMT-MPL has to be considered even for those patients who are inconspicuous in the first months of life or show somatic anomalies typical for other inherited bone marrow failure syndromes.

## Introduction

Congenital amegakaryocytic thrombocytopenia (CAMT, MIM #604498) is a rare inherited bone marrow failure syndrome (IBMFS) which usually presents as severe thrombocytopenia at birth without specific characteristics and progresses to aplastic anemia during the first years of life.<sup>1,2</sup> Deleterious mutations in *MPL* coding for the thrombopoietin receptor have first been identified as single molecular cause of CAMT,<sup>3,4</sup> but the disease is now regarded to be genetically heterogeneous.<sup>5</sup> Indeed, mutations in the gene for thrombopoietin (*THPO*) have been recently described in some of these patients.<sup>6-8</sup> Furthermore, newborns with other IBMFS like Dyskeratosis congenita, Fanconi anemia, MECOM associated syndrome or microdeletion syndromes can present phenotypically as CAMT since pathognomonic signs of these syndromes might be not yet apparent.<sup>9-12</sup> In the following we use the term CAMT-MPL for the IBMFS caused by allelic mutations in *MPL*.

Previous descriptions of CAMT-MPL are based on single case reports or small case series, not allowing for a comprehensive evaluation of the phenotypic spectrum of the disease.<sup>1,2,13</sup> Over the last 20 years we analyzed samples and clinical data from patients suspicious for inherited thrombocytopenia and could identify 56 patients with CAMT-MPL. The aims of our analysis of clinical, genetic and laboratory data are (i) a detailed description of the clinical picture of CAMT-MPL, (ii) the establishment of genotype-phenotype correlations allowing for the prediction

Haematologica 2021  
Volume 106(9):2439-2448

## Correspondence:

MANUELA GERMESHAUSEN  
germeshausen.manuela@mh-hannover.de

MATTHIAS BALLMAIER  
ballmaier.matthias@mh-hannover.de

Received: May 5, 2020.

Accepted: July 17, 2020.

Pre-published: July 23, 2020.

<https://doi.org/10.3324/haematol.2020.257972>

©2021 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: <https://creativecommons.org/licenses/by-nc/4.0/legalcode>, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



of development of aplastic anemia and malignancies, and (iii) a better understanding of the thrombopoietin-MPL system *in vivo*.

## Methods

### Patients

Patient material and clinical data were provided after informed consent. The study was approved by the local ethics committee. Patients suspected to have CAMT were analyzed for mutations in *MPL*. Twenty-three of the 56 CAMT-MPL patients included in this study were part of earlier publications of our group,<sup>4,14,15</sup> two were the subject of single case studies.<sup>16,17</sup> Six further patients had an already known heterozygous *MPL* mutation and a seemingly unaffected second allele.

### Sequencing

Mutational analyses were performed by Sanger sequencing from leukocyte derived genomic DNA as described previously.<sup>4</sup>

### *In silico* analysis of mutation data

PROVEAN,<sup>18</sup> SIFT,<sup>19</sup> Polyphen2,<sup>20</sup> and MutationTaster<sup>21</sup> algorithms were used for prediction of the effect of *MPL* mutations on protein function. Putative splicing mutations were evaluated by BDGP splice site prediction,<sup>22</sup> MaxEntScan algorithm,<sup>23</sup> and Human Splicing Finder (HSF 3.1).<sup>24</sup>

### Flow cytometric analyses

Flow cytometric analyses of CD110 expression on early hematopoietic progenitors were performed as described earlier.<sup>25</sup>

### Thrombopoietin levels

Thrombopoietin serum or plasma levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, R&D systems).

## Results

### MPL mutations\*

We identified 56 patients with homozygous (n=39) or compound heterozygous (n=17) mutations in *MPL* (Tables 1; *Online Supplementary Table S1*). We detected 38 different mutations (Figure 1, Table 2), 17 out of them are novel (Tables 1 and 2; *Online Supplementary Table S2*).


Six different nonsense mutations (allele frequency 20%; including three novel mutations) and three different frame shift deletions (allele frequency 13%) affected 20 different patients (Table 2A and B; *Online Supplementary Table S2*).

Five different splice site mutations (allele frequency 10%, two novel) affected 11 patients (ten families). With the exception of c.391+5G>C, all are predicted to lead to a complete loss of function (Table 2C). Prediction was confirmed for c.79+2T>A by measurement of missing CD110 surface expression on hematopoietic progenitors (Figure 2, see below) and for 213-1G>A and c.79+2T>A by the severe course of the disease in the affected patients. In contrast, patients with the mutation c.391+5G>C, allowing a residual natural splicing,<sup>26</sup> had a less severe course and measurable CD110 expression on hematopoietic progenitors (Figure 2).

The majority of mutations in our patient cohort were missense mutations (24 different mutations in 35

patients, allele frequency 57%, 12 novel, Table 2D) Two hotspots (amino acids 102-104: 18 alleles, 12 patients; proline residues 135-136: six alleles, five patients) account for 21% of all mutated alleles. Fifteen of 24 missense mutations are predicted to be deleterious by all applied algorithms, 23 of 24 by at least one of the algorithms (Table 2D).

Due to the small number of individual cases it is difficult to predict clinical courses from the individual missense mutations. Specifically severe courses were observed in patients affected from p.Arg102Pro, p.Trp154Arg, and p.Leu169His. The latter one was found in three unrelated patients from Chile suggesting a founder mutation with regional significance.



**Figure 1. MPL alleles in CAMT patients** All *MPL* mutations found in our cohort of congenital amegakaryocytic thrombocytopenia (CAMT) patients are depicted on the left side beneath the exon structure of the *MPL* transcript with corresponding numbering of bases (coding sequence). Every symbol represents a mutated allele in one patient. The derived protein structure with the functional domains of the receptor protein and corresponding numbering of amino acids is shown on the right. Circles: missense mutations; diamonds: nonsense mutations; triangles: frame shift deletions; equal signs: splice site mutations. Mutations with less severe phenotypes are marked in green color (see main text). SP: signal peptide, TM: transmembrane domain

Less severe courses (thrombocytopenia not detected at birth or onset of pancytopenia not in early childhood) were observed in patients with mutations p.Met8Arg, p.Asp295Tyr, p.Pro394Ser and missense mutations in exons 11 and 12 affecting the intracytoplasmic part of the receptor molecule (p.Leu524Arg, p.Pro581Leu, p.Leu594Trp). p.Met8Arg is the most N-terminal mutation in *MPL* described so far. The mutation is located in the signal peptide region of the *MPL* precursor protein and might affect signaling of the molecule as well as the function of this codon as a possible alternative translation initiation site. It was homozygously found in a patient from consanguineous parents first diagnosed with thrombocytopenia at the age of 9 months.

The mutation p.Arg454Pro which is predicted to be benign by all applied prediction algorithms was homozy-

gously found in a patient presenting at the age of 2 years with a profound isolated hypomegakaryocytic thrombocytopenia.

p.Arg102His is the third mutation affecting Arg102 in CAMT: p.Arg102Cys and p.Arg102Pro cause a severe phenotype of CAMT in patients<sup>15</sup> and disturb intracellular trafficking of the *MPL* protein<sup>27</sup> although p.Arg102His as well as p.Arg102Pro are predicted to be benign by SIFT and PROVEAN algorithms (Table 2D).

\* The nomenclature of sequence variants follows the recommendations of the Human Genome Variation Society (HGVS). A description at the DNA level is provided in the Online Supplementary Table S2. Missense mutations are described at protein level, other mutations on DNA level (coding sequence). Amino acid substitutions are deduced from DNA sequencing results, the recommended parentheses have been omitted for better readability.

**Table 1. Congenital amegakaryocytic thrombocytopenia patients included in this study.**

patient ID	sex	intron/exon	CDS	protein
CAMT001	f	E2	c.127C>T	p.Arg43Ter
CAMT006	f	E3	c.268C>T	p.Arg90Ter
CAMT007	m	E3	c.305G>C	p.Arg102Pro
CAMT009	f	E3	c.378delT	p.Phe126LeufsTer5
CAMT011	f	E5	c.823C>A	p.Pro275Thr
		E3	c.305G>C	p.Arg102Pro
CAMT012	m	E3	c.305G>C	p.Arg102Pro
CAMT013	f	E3	c.235_236delCT	p.Leu79GlufsTer84
CAMT015	f	E3	c.305G>C	p.Arg102Pro
CAMT017	f	E2	c.127C>T	p.Arg43Ter
CAMT018	f	E2	c.127C>T	p.Arg43Ter
CAMT019	f	E2	c.127C>T	p.Arg43Ter
CAMT030	m	I1	c.79+2T>A	p.Asp27fs
CAMT031	f	E3	c.378delT	p.Phe126LeufsTer5
CAMT033	f	E3	c.378delT	p.Phe126LeufsTer5
		I2	c.213-1G>A	splicing defect
CAMT034	f	E3	c.378delT	p.Phe126LeufsTer5
CAMT036	m	E2	c.127C>T	p.Arg43Ter
CAMT039	f	E3	c.378delT	p.Phe126LeufsTer5
		E3	c.367C>T	p.Arg123Ter
CAMT043	f	E3	c.304C>T	p.Arg102Cys
CAMT050	f	E4	c.460T>C	p.Trp154Arg
CAMT052	f	E8	c.1305G>C	p.Trp435Cys
CAMT055	m	E5	c.770G>T	p.Arg257Leu
CAMT058	m	E4	c.407C>T	p.Pro136Leu
		E12	c.1781T>G	p.Leu594Trp
CAMT059	m	E8	c.1230G>A	p.Trp410Ter
CAMT067	m	E3	c.305G>C	p.Arg102Pro
		E3	c.311T>C	p.Phe104Ser
CAMT075	m	E3	c.305G>C	p.Arg102Pro
CAMT082	m	E3	c.305G>C	p.Arg102Pro
		I3	c.391+5G>C	splicing defect
CAMT083	m	E8	c.1305G>C	p.Trp435Cys
CAMT087	m	E2	c.127C>T	p.Arg43Ter
CAMT092	f	I3	c.391+5G>C	splicing defect
		E9	c.1378C>T	p.Gln460Ter
CAMT098	m	I1	c.79+2T>A	splicing defect
		E4	c.404C>G	p.Pro135Arg
CAMT101	m	E6	c.883G>C	p.Asp295Tyr
CAMT102	f	E6	c.883G>C	p.Asp295Tyr
CAMT108	f	E3	c.378delT	p.Phe126LeufsTer5
		I11	c.1653delG	p.Lys553ArgfsX75
CAMT113	f	I2	c.212+1G>A	splicing defect
		I3	c.391+5G>C	splicing defect
CAMT122	f	E12	c.1742C>T	p.Pro581Leu
CAMT123	f	E4	c.460T>C	p.Trp154Arg
CAMT125	f	E4	c.407C>A	p.Pro136His
CAMT130	f	I3	c.391+5G>C	splicing defect
		E5	c.769C>T	p.Arg257Cys
CAMT133	f	E8	c.1180C>T	p.Pro394Ser
CAMT136	m	E9	c.1361G>C	p.Arg454Pro
CAMT137	f	I3	c.391+5G>C	splicing defect
		E5	c.769C>T	p.Arg257Cys
CAMT138	f	E9	c.1390A>G	p.Arg464Gly
CAMT140	m	E8	c.1180C>T	p.Pro394Ser
CAMT144	f	E3	c.304C>T	p.Arg102Cys
		E4	c.407C>T	p.Pro136Leu
CAMT157	m	E4	c.506T>A	p.Leu169His
CAMT159	f	E1	c.23T>G	p.Met8Arg
CAMT160	m	E3	c.235_236delCT	p.Leu79GlufsX84
CAMT163	f	E9	c.1431G>A	p.Trp477Ter
CAMT167	f	E5	c.805T>C	p.Trp269Arg
CAMT168	m	E11	c.1571T>G	p.Leu524Arg
CAMT169	m	E3	c.305G>A	p.Arg102His
		E3	c.235_236delCT	p.Leu79GlufsX84
CAMT178	f	E3	c.305G>C	p.Arg102Pro
		E4	c.506T>A	p.Leu169His
CAMT179	f	E4	c.407C>G	p.Pro136Arg
		E6	c.944T>G	p.Phe315Cys
CAMT180	m	E2	c.127C>T	p.Arg43Ter
CAMT181	f	E3	c.305G>C	p.Arg102Pro
		I9	c.1469-2A>T	splicing defect
CAMT183	f	E4	c.506T>A	p.Leu169His

Congenital amegakaryocytic thrombocytopenia (CAMT) patients included in this study. Patients are listed with *MPL* mutations (bold: novel mutations) and predicted effect on the *MPL* protein; f: female, m: male; ID: identifier; I: intron; E: exon; CDS: coding DNA sequence.

### CD110 expression on hematopoietic progenitors

We analyzed the expression of the *MPL* encoded protein CD110 on CD34<sup>+</sup>CD38<sup>lo</sup> hematopoietic progenitors<sup>25</sup> from 30 CAMT-MPL patients and eight healthy donors (Figure 2). There was a clear correlation between real CD110 expression and the predicted effects from the mutation analysis on the one hand and between CD110 expression and clinical course on the other hand: CD110 expression was not measurable on cells from patients with nonsense or frame shift mutations and mutations predicted to lead to a complete loss of a splice site (Figure 2, group A). In the group of patients with missense mutations we observed more variation in CD110 surface expression (Figure 2, group B) which was correlated with clinical courses: the higher CD110 expression observed in two patients homozygously affected by p.Asp295Tyr (Figure 2, violet squares) was correlated with a less severe course (CAMT101 and CAMT102). Cells from the patient with the p.Arg454Pro mutation predicted to be benign showed a nearly normal surface expression of CD110 (Figure 2, green square). In contrast, in patients with the mutation p.Arg102Pro (homozygous or compound heterozygous with a null mutation) and a relative

severe course we measured a very low CD110 signal (Figure 2, blue squares).

### Thrombopoietin plasma levels

Plasma levels of thrombopoietin are inversely proportional to the total mass of functional MPL in the body due to a direct negative feedback loop. Healthy donors usually have thrombopoietin plasma levels below 30 pg/mL (range <30-196 pg/mL). In contrast, thrombopoietin plasma levels were markedly elevated in all samples from 40 patients in this study and ranged from 400 to >4,000 pg/mL (median 1,493 pg/mL; *Online Supplementary Table S1*). Within the group of CAMT-MPL patients we did not find a significant correlation between THPO levels and either MPL expression levels on early hematopoietic progenitors or severity of the disease, but patients predicted to have a total receptor deficiency had a higher median thrombopoietin level (median 1,685 pg/mL, n=13) compared to patients with mutations allowing for a residual activity of the receptor (median 1,472 pg/mL, n=27). In our study, the measurement of MPL expression on hematopoietic precursors was a better predictor of the clinical course than THPO levels. Unexpectedly low

**Table 2. *MPL* mutations in congenital amegakaryocytic thrombocytopenia patients. All mutations found in our group of congenital amegakaryocytic thrombocytopenia (CAMT) patients are listed regarding their type in Tables 2A to D together with their predicted impact on the *MPL* protein and their incidence in our patient group (bold: novel mutations). 2A (nonsense mutations) and 2B (frame shift mutations): prediction according to MutationTaster<sup>21</sup> with probability; 2C (splice mutations): prediction according to BDGP splice site prediction,<sup>22</sup> MaxEntScan algorithm (MaxEnt),<sup>23</sup> and Human Splicing Finder (HSF).<sup>24</sup> MDD: maximal dependency decomposition (only for donor sites), MM: Markov model (1st order), WMM: weighted matrix method. 2D (missense mutations): prediction according to MutationTaster,<sup>21</sup> PROVEAN,<sup>18</sup> and SIFT<sup>19</sup> algorithms with the respective score values. \*The mutation previously referred to as c.1653+1delG (now c.1653delG) should be also regarded as a frame shift mutation since the predicted effect on the splice donor site is marginal (Table 2C) and the effect on the protein is caused mainly by the frame shift.<sup>56</sup>**

**Table 2A. Nonsense mutations in congenital amegakaryocytic thrombocytopenia patients.**

CDS	Exon	protein	MutationTaster	incidence
c.127C>T	E2	p.Arg43Ter	disease causing / 1	ho: n=7; het: n=0
c.268C>T	E3	p.Arg90Ter	disease causing / 1	ho: n=1; het: n=0
c.367C>T	E3	p.Arg123Ter	disease causing / 1	ho: n=0; het: n=1
c.1230G>A	E8	p.Trp410Ter	disease causing / 1	ho: n=1; het: n=0
c.1378C>T	E9	p.Gln460Ter	disease causing / 1	ho: n=0; het: n=1
c.1431G>A	E9	p.Trp477Ter	disease causing / 1	ho: n=1; het: n=0

CDS: coding DNA sequence; ho: homozygous individuals; het: heterozygous individuals.

**Table 2B. Frame shift mutations in congenital amegakaryocytic thrombocytopenia patients.**

CDS	Exon	protein	MutationTaster	incidence
c.235_236delCT	E3	p.Leu79Glufs*84	disease causing / 1	ho: n=2; het: n=1
c.378delT	E3	p.Phe126LeufsX5	disease causing / 1	ho: n=3; het: n=3
c.1653delG*	E11	p.Lys553ArgfsX75	disease causing / 1	ho: n=0; het: n=1

CDS: coding DNA sequence; E: exon; ho: homozygous individuals; het: heterozygous individuals.

**Table 2C. Splice site mutations in congenital amegakaryocytic thrombocytopenia patients.**

CDS	Intron	HSF prediction	MaxEnt (wt/mut)	MDD (wt/mut)	MM (wt/mut)	WMM (wt/mut)	incidence
c.79+2T>A	I1	most prob. broken donor s.	9.16/0.97	13.98/5.79	9.62/1.43	10.39/2.21	ho: n=1; het: n=1
c.212+1G>A	I2	most prob. broken donor s.	9.00/0.82	11.78/3.60	9.27/1.08	7.15/-1.03	ho: n=0; het: n=1
c.213-1G>A	I2	most prob. broken acc. s.	7.90/-0.85	-	7.69/-1.06	6.71/-2.04	ho: n=0; het: n=1
c.391+5G>C	I3	most prob. broken donor s.	9.14/6.25	12.18/9.98	8.32/4.76	9.69/5.86	ho: n=0; het: n=5
c.1469-2A>T	I9	most prob. broken acc. s.	8.25/-0.11	-	9.41/1.05	11.03/2.67	ho: n=0; het: n=1
(c.1653+1delG*	I11	new donor site 1 base 5'	10.90/8.40	15.68/12.58	10.63/7.39	9.35/6.49	ho: n=0; het: n=1)

CDS: coding DNA sequence; I: Intron; ho: homozygous; het: heterozygous. HSF: Human Splicing Finder; Max/En: MaxEntScan algorithm; wt: wild-type; mut: mutant; MM: Markov model; WMM: weighted matrix method.

Table 2D. Missense mutations in congenital amegakaryocytic thrombocytopenia patients

CDS	Exon	protein	MutationTaster	PROVEAN	SIFT	incidence
c.23T>G	E1	p.Met8Arg	polymorphism / 0.963	polymorphism / 0.963	damag. / 0.004	ho: n=1; het: n=0
c.304C>T	E3	p.Arg102Cys	disease causing / 1.000	disease causing / 1.000	toler. / 0.064	ho: n=1; het: n=1
c.305G>A	E3	p.Arg102His	disease causing / 0.983	disease causing / 0.983	toler. / 0.291	ho: n=0; het: n=1
c.305G>C	E3	p.Arg102Pro	disease causing / 0.995	disease causing / 0.995	toler. / 0.082	ho: n=4; het: n=5
c.311T>C	E3	p.Phe104Ser	disease causing / 0.975	disease causing / 0.975	damag. / 0.001	ho: n=0; het: n=1
c.404C>G	E4	p.Pro135Arg	disease causing / 0.995	disease causing / 0.995	damag. / 0.000	ho: n=0; het: n=1
c.407C>A	E4	p.Pro136His	disease causing / 0.991	disease causing / 0.991	damag. / 0.000	ho: n=1; het: n=0
c.407C>T	E4	p.Pro136Leu	disease causing / 1.000	disease causing / 1.000	damag. / 0.000	ho: n=0; het: n=2
c.407C>G	E4	p.Pro136Arg	disease causing / 0.995	disease causing / 0.995	damag. / 0.000	ho: n=0; het: n=1
c.460T>C	E4	p.Trp154Arg	disease causing / 0.984	disease causing / 0.984	damag. / 0.000	ho: n=2; het: n=0
c.506T>A	E4	p.Leu169His	disease causing / 0.903	disease causing / 0.903	damag. / 0.001	ho: n=1; het: n=1
c.769C>T	E5	p.Arg257Cys	disease causing / 1.000	disease causing / 1.000	damag. / 0.002	ho: n=0; het: n=2
c.770G>T	E5	p.Arg257Leu	disease causing / 1.000	disease causing / 1.000	damag. / 0.005	ho: n=1; het: n=0
c.805T>C	E5	p.Trp269Arg	disease causing / 0.994	disease causing / 0.994	damag. / 0.000	ho: n=1; het: n=0
c.823C>A	E5	p.Pro275Thr	disease causing / 0.985	disease causing / 0.985	damag. / 0.008	ho: n=0; het: n=1
c.883G>C	E6	p.Asp295Tyr	disease causing / 0.998	disease causing / 0.998	damag. / 0.002	ho: n=2; het: n=0
c.944T>G	E6	p.Phe315Cys	disease causing / 0.999	disease causing / 0.999	damag. / 0.003	ho: n=0; het: n=1
c.1180C>T	E8	p.Pro394Ser	disease causing / 0.981	disease causing / 0.981	damag. / 0.004	ho: n=2; het: n=0
c.1305G>C	E8	p.Trp435Cys	disease causing / 1.000	disease causing / 1.000	damag. / 0.000	ho: n=2; het: n=0
c.1361G>C	E9	p.Arg454Pro	polymorphism / 1.000	polymorphism / 1.000	toler. / 0.391	ho: n=1; het: n=0
c.1390A>G	E9	p.Arg464Gly	polymorphism / 0.993	polymorphism / 0.993	damag. / 0.006	ho: n=1; het: n=0
c.1571T>G	E11	p.Leu524Arg	disease causing / 0.807	disease causing / 0.807	damag. / 0.002	ho: n=1; het: n=0
c.1742C>T	E12	p.Pro581Leu	disease causing / 0.981	disease causing / 0.981	damag. / 0.004	ho: n=1; het: n=0
c.1781T>G	E12	p.Leu594Trp	polymorphism / 0.986	polymorphism / 0.986	damag. / 0.000	ho: n=0; het: n=1

CDS: coding DNA sequence; ho: homozygous individuals; het: heterozygous individuals.

THPO values, despite complete MPL deficiency, could be due to recent platelet transfusions or duration and condition of sample shipment.

## Clinical phenotype

### Inheritance

Twenty-nine (52%) of the patients in our cohort had consanguineous parents and were homozygous for the particular *MPL* mutation. Homozygous mutations in patients with no evidence for parental consanguinity (n=9) were mainly affected from the most prevalent mutation c.305G>C (n=4) or from mutations with a higher prevalence in a specific region (c.506T>A, see above) or ethnic group (c.79+2T>A).<sup>28</sup>

Some families had more than one affected patient: CAMT009 + CAMT031, CAMT018 + CAMT019 + CAMT036 + CAMT180, and CAMT133 + CAMT140 each belongs to large kindreds with a high degree of consanguinity. Other cases of CAMT, aplastic anemia or not otherwise specified "bleeding disease" are reported in these kindreds. CAMT101 and CAMT102 as well as CAMT130 and CAMT137 are siblings from non-consanguineous families. CAMT083 is the fetus of a second pregnancy of the mother of CAMT052. Bone marrow analysis during autopsy revealed normal cellularity with absent megakaryocytes.

### Pregnancies, deliveries, symptoms at birth

Pregnancies and deliveries were unremarkable in the majority of the cases. Median gestational age was 40


weeks (n=34, range, 31-42 weeks of gestation [wGA]), mean birth weight 3,080 g (n=25, range, 1,545-4,280 g).

Intracranial bleeding *in utero* was detected in some patients (seven of 46),<sup>†</sup> retrospectively in four of seven. Two children were delivered by cesarean section due to diagnosis of cerebral hemorrhage: CAMT013 with a *hydrops fetalis* due to Rhesus incompatibility (wGA 31) and CAMT123 after an intracranial bleeding in wGA 28 (wGA 38). Pregnancy of CAMT083 was terminated in wGA 22 because of very poor prognosis after intracranial bleeding. There were three other cesarean sections for reasons only related to the mother.

We found a significant female predominance in our cohort (62.5%,  $P < 0.05$  according to  $\chi^2$ -test).<sup>2</sup> This is in contrast to most of the other IBMFS in which boys are affected more often.<sup>29</sup> We have no information about the number and sex ratio of miscarriages in the patients' families as a possible hint for the female predominance.

### Thrombocytopenia, bleeding

Although thrombocytopenia at birth has been classified as one of the diagnostic hallmarks of CAMT so far, 13 of 52<sup>†</sup> patients in this study with available information showed no signs of thrombocytopenia at birth and no blood counts were taken. Twelve of 13 patients had mutations allowing for a residual MPL activity. In the remaining patients (39 of 52)<sup>†</sup> thrombocytopenia was detected at birth (n=38) or at termination of pregnancy (n=1). Available data for platelet counts at birth ranged from 1-36 G/L (median 15 G/L, n=30). Petechiae or pur-



**Figure 2.** MPL expression on CD34+CD38lo hematopoietic progenitors from congenital amegakaryocytic thrombocytopenia patients. The figure shows CD110 expression levels, calculated from cumulative subtraction on CD34+CD38lo hematopoietic progenitors of patients with nonsense, frame shift mutations or splice site mutations predicted to lead to a complete loss of MPL function (A), missense mutations (B), or patients who are compound heterozygous for different types of mutations (mix), in comparison to normal donors (ND). Horizontal lines represent the mean and standard error of the mean. Data from samples with special genotypes are labeled with the same colors, respectively. A+B: red: p.Arg43Ter, orange: p.Phe126LeufsTer5, grey: c.79+2T>A; green: p.Arg454Pro, pink: p.Leu169His, violet: p.Asp295Tyr, blue: p.Arg102Pro (half: compound heterozygous with p.Phe104Ser); mix: dark green/blue: c.391+5G>C/p.Arg102Pro, dark green/black: c.391+5>C/p.Arg257Cys.

pura at birth or in the first week of life were the presenting symptoms of thrombocytopenia in the majority of cases (25 of 38)<sup>†</sup>. Only few patients (five of 38)<sup>†</sup> presented with severe bleedings at birth (n=3) or shortly thereafter (n=2). Intracranial bleedings were reported only during pregnancy (n=7), at birth (n=2) or within the first 4 weeks of life (n=4). Hematemesis as an indication of gastrointestinal bleeding was observed in one patient (at birth). In contrast to intracranial and gastrointestinal bleeding, severe episodes of epistaxis were reported mainly during the later stages of the disease (n=3).

Data regarding platelet courses confirmed our concept of CAMT I and CAMT II distinguishing between patients with severely low platelet counts over the whole course of the disease due to loss-of-function mutations in *MPL* (CAMT I) and those patients showing a spontaneous increase of platelet counts in the first months of life due to a residual function of the receptor (CAMT II):<sup>4,14,15</sup> platelet counts over 50 G/L (not transfused) within the first year of life have been documented for 14 of 33<sup>†</sup> patients. For nine more patients with a late diagnosis of thrombocytopenia we can also assume higher platelet counts in the first months of life. None of these 23 patients bore a mutation predicted to lead to a complete loss of function. Nearly all CAMT I and CAMT II patients demonstrated a further decline of platelet counts during the development of aplastic anemia. Platelet counts of heterozygously affected parents and siblings of patients were in a normal range with the exception of one parent (c.305G>C) with mild thrombocytopenia (130-150 G/L).

#### Development of pancytopenia

Development of additional anemia or neutropenia and reduced bone marrow cellularity are signs of developing bone marrow exhaustion. Bone marrow analyses from the first 6 months of life usually showed normal cellularity with reduced or absent megakaryocytes (13 of 15).<sup>†</sup> Accordingly, most of the patients presented with isolated

**Table 3.** Non-hematological findings in congenital amegakaryocytic thrombocytopenia patients.

	# of patients (with ICH)	HPO-designation
Data available	50	
No non-hematological findings	25	
Abnormality of fetal development	1 (1)	HP:0001197
hydrops fetalis	1 (1)	HP:0001789
Anomalies of the nervous system	7 (6)	HP:0000707
optic nerve hypoplasia	1 (1)	HP:0000609
cerebellar hypoplasia	1 (1)	HP:0001321
agenesis of corpus callosum	1 (1)	HP:0001274
Dandy-Walker anomaly	2 (2)	HP:0001305
arachnoid cyst	3 (2)	HP:0100702
ventriculomegaly	1 (1)	HP:0002119
colpocephaly	1 (1)	HP:0030048
hydrocephalus	1 (1)	HP:0000238
Mental/psychomotor retardation	7 (5)	HP:0001263
Abnormality of the skin	4	HP:0000951
eczema	2 (0)	HP:0000964
hypopigmentation	1 (0)	HP:0001010
atopic dermatitis	1 (0)	HP:0001047
Abnormalities of the eye	10	HP:0000478
impaired vision	1 (1)	HP:0000505
nystagmus	4 (3)	HP:0000639
strabismus	9 (5)	HP:0000486
Abnormalities of the face	4 (1)	HP:0000271
hypertelorism	2 (1)	HP:0000316
high palate	2 (0)	HP:0000218
small uvula	1 (0)	HP:0010812
Skeletal abnormalities	0	HP:0000924
Cardiovascular abnormalities	0	HP:0001626
Abnormalities of the genitourinary system	0	HP:0000119
Other abnormalities	2 (0)	
obstructive sleep apnea	1 (0)	HP:0002870
diabetes	1 (0)	HP:0000819
short stature	1 (0)	HP:0004322

Non-hematologic abnormalities found in congenital amegakaryocytic thrombocytopenia (CAMT) patients with homozygous or compound heterozygous mutations in *MPL* with the respective designations according to the human phenotype ontology (HPO)<sup>57</sup>. Number of patients with documented intracranial hemorrhages (ICH) in parentheses.

thrombocytopenia at birth or in the first weeks thereafter (36 of 51).<sup>†</sup> Only six patients showed signs of multi-lineage cytopenia within the first 6 months of life, four of them were already anemic immediately after birth (hemoglobin 56-76 g/L). For two patients a hypocellular bone marrow is documented in the first month after birth.

Provided the data available at time of analysis only seven of 49 patients showed no signs of developing pancytopenia. Five of these patients were younger than 2 years at last examination.

From the remaining 42 patients with documented aplasia only 24% were older than 4 years (n=10). Seventy-six percent (n=32) were younger than 4 years, half of them even younger than 2 years (*Online Supplementary Figure S1*). CAMT011 is the only patient without any signs of pancytopenia till adulthood.

<sup>†</sup> Here and in all subsequent ratios, the denominator is the number of patients for whom information is available for a specific parameter. E.g., for "intracranial bleeding" 46 is the number of questionnaires with a yes-no-information from the attending physicians.

Table 4. Hematopoietic stem cell transplantation in congenital amegakaryocytic thrombocytopenia.

	# of pts with available info		N	%	Pos outcome (%)	information about neg. outcome
Age at 1 <sup>st</sup> HSCT [y]	38	Median: 3.55 y, range: 0.6 – 11 y				
		<1 year	5	13	4/4 (100)	
		1-5 years	23	61	15/17 (88)	CAMT039: TRD (no details, BM, MUD) CAMT015: death after GvHD-induced bronchiolitis obliterans (BM, MUD)
		>5 years	10	26	7/9 (78)	CAMT007: death after graft rejection and sepsis (PBSC, MUD) CAMT157: death after GvHD grade 4 (lung, skin) and sepsis (CB)
HSC donor	34	HLA matched related donor	19	56	12/12 (100)	
		haploident related donor	3	9	4/4 (100)	
		matched unrelated donor	11	32	5/8 (63)	
		mismatched unrelated donor	1	3	1*/1 (100)	
HSC source	22	BM	10	48	8/10 (80)	
		PBSC	7	33	6/7 (86)	
		CB	5	19	3/4 (75)	

The table summarizes the available information regarding age of hematopoietic stem cell transplantation (HSCT), donor and source of hematopoietic stem cell (HSC) and outcome. Information about outcome was not available for all transplantations. BM: bone marrow; CB: cord blood; PBSC: peripheral blood stem cells; pts: patients; TRD: transplantation related death;\*: CB, 1 mismatch. GvHD: graft-versus-host disease; MUD: matched unrelated donor.

#### Chromosomal anomalies, leukemic development

Cytogenetic data were inconspicuous for most of the patients with available data (n= 23 of 27, 85%). An abnormal karyotype has been detected in 4 patients: t2;11 (5%) in CAMT009,<sup>14</sup> a not further specified additional marker chromosome (94%) in CAMT013<sup>14</sup> and monosomy 7 in CAMT043<sup>30</sup> (50%) and CAMT067 (13-30%). The latter has been diagnosed with MDS. All underwent hematopoietic stem cell transplantation (HSCT) because of aplastic anemia. In none of the patients a development of overt leukemia has been reported in the period of record.

#### Non-hematological abnormalities

The rate of non-hematological abnormalities in our CAMT-MPL patients was markedly higher than reported: 50% of the patients with available data (25 of 50) had non-hematological abnormalities appearing as structural abnormalities or other abnormal clinical findings (Table 3). Most of the reported anomalies were related to the head region: brain anomalies (n=7), ocular and orbital anomalies (n=10), especially strabismus (n=9), nystagmus (n=4) and facial abnormalities (n=4). Mental or psychomotor retardation was observed in seven patients, mostly correlated with brain anomalies. Intracranial bleedings are documented for five of seven patients with mental or psychomotor retardation, for six of seven with brain anomalies, and for six of ten with ocular anomalies (Table 3). Interestingly, we found some anomalies which are typical for other IBMFS and which misled the first diagnosis: eczema (n=2), hypopigmentation (n=1), high palate and/or small uvula (n=2). No skeletal, cardiac or urogenital abnormalities were observed. There was no correlation between type or localization of *MPL* mutations and non-hematological abnormalities.

#### Treatment

Thirty-seven of 45 documented cases of our patient group received platelet transfusions, most of them transiently in a period immediately after diagnosis of severe thrombocytopenia and/or during the aplastic stage of the disease. During the advanced stage of the pancytopenia the patients often received erythrocyte transfusions (16 of 45). Neutropenia and associated infections were treated with antibiotics; two of the patients were treated with recombinant granulocyte colony-stimulating factor.

Half of the patients (25 of 50) have been initially treated with immunoglobulins (23 of 50) or corticosteroids (15 of 50). Interestingly, three patients responded with a transient increase in platelet counts, which initially misled the diagnosis but none showed a persistent response.

The only available curative treatment for CAMT-MPL is HSCT. Thirty-eight of 51 patients in our group were treated with HSCT, for another ten HSCT was planned for the near future. For 26 of 30 patients with information about the post-transplant course a positive outcome was documented (87%). The available information about age of transplantation, donor, stem cell source and outcome is summarized in Table 4.

Three patients were unsuccessfully treated with recombinant IL-11 (oprelvekin). Two of them showed a slight and transient increase in platelet counts, followed by a prolonged phase of severe thrombocytopenia, which could be explained by an exhaustion of residual megakaryopoiesis by stimulation of cytoplasmic maturation.

#### Congenital amegakaryocytic thrombocytopenia with only one affected *MPL* allele

In six patients with clinical diagnosis of CAMT we found only a single mutated allele (*Online Supplementary Table S3*), as judged by reproducible balanced distribution

of both alleles from independently isolated genomic DNAs in five patients and an unbalanced distribution of both alleles in one patient. Two of these six patients were from families with other members affected by CAMT-MPL: CAMT139 was heterozygously affected by the missense mutation c.1390A>G, homozygously detected in her sister CAMT138. Both sisters had similar clinical and laboratory findings. Both parents were heterozygous carrier of the mutation without any hematological problems. Thrombopoietin plasma levels were high in both sisters but not in the parents. However, in contrast to both parents who demonstrated a balanced distribution of both alleles the wild-type allele in CAMT139 was reproducibly markedly underrepresented (approximately 20%), arguing for somatic mosaicism. Patient CAMT065 heterozygously harbored the c.127C>T nonsense mutation, which was homozygously found in his cousins CAMT036 and CAMT018. Besides these familial cases we identified four other patients with heterozygous *MPL* mutations. In one of these patients (CAMT129) we found CD110 expression on early hematopoietic progenitors comparable to that from patients with a predicted complete loss of the receptor (Figure 2). In patient CAMT73 we found a novel nonsense mutation in exon 7 together with a synonymous substitution c.585T>C (p.Pro195=). Although synonymous mutations can significantly influence protein levels via changes in translation efficiency,<sup>31</sup> both codons are nearly equally used in human genes, and the mutation has no predicted effect on splicing.

## Discussion

This report summarizes the results of a long term study on the largest cohort of patients with CAMT-MPL caused by biallelic mutations in *MPL*. We limited our cohort to this group of patients (i) to provide a reliable definition of the clinical picture of CAMT-MPL, (ii) to define the effects of the *MPL*/*THPO* system in humans, and (iii) to allow for evidence based treatment recommendations.

CAMT has been used in the past to describe an IBMFS with no characteristic malformations presenting as isolated thrombocytopenia at birth progressing to a general bone marrow failure.<sup>13,32</sup> However, large differences in the reported percentages for *MPL* mutations, for the development of aplastic anemia and leukemia, and for somatic malformations reveal differences in the definition of this disease.<sup>29,33-35</sup> This together with misleading combinations of findings from the pre-molecular era involves the risk of mistreatment e.g., HSCT of patients with CAMT due to *THPO* mutations.

The most severe clinical problems for patients with CAMT-MPL are (i) - so far underestimated - pre- and perinatal bleedings and the resulting long-term consequences thereof, and (ii) the development of aplastic anemia in the later course of the disease.

Severe bleedings, especially intracranial bleedings, occur mainly pre- or perinatally but much less frequently after the first weeks of life despite partly very low platelet counts. Specific functional deficits in neonatal platelets like a decreased P-Selectin expression and reduced platelet activation and secretion<sup>36-38</sup> could be a possible explanation for the high bleeding tendency pre- or perinatally in combination with the thrombocytopenia. Furthermore, both life-span

and thrombin dependent activation of platelet GPIIb/IIIa are markedly reduced in neonatal *Mpl*<sup>-/-</sup> mice compared to adult *Mpl*<sup>-/-</sup> mice.<sup>37</sup> Our results indicate a possible functional impairment of platelets also in human fetuses and newborns with *MPL* defect which is in contrast to the assumption of a normal function of *Mpl*<sup>-/-</sup> platelets.<sup>39</sup>

Development of aplastic anemia due to exhaustion of three lineage hematopoiesis is a characteristic feature of CAMT-MPL and reveals the essential role of *MPL* for the maintenance of hematopoietic stem cells:<sup>40</sup> almost all patients inevitably develop a fatal bone marrow failure. In our study we observed only one patient with an isolated thrombocytopenia until adulthood. In the literature one further patient is described with stable thrombocytopenia in the period of record.<sup>41</sup>

Half of the patients in our cohort exhibit non-hematopoietic abnormalities. This is in contrast to the characterization of CAMT as an IBMF with no physical anomalies (OMIM). Most of the non-hematopoietic abnormalities seen in our cohort are related to the brain and the eye. For neurological abnormalities, which have been reported for other CAMT-MPL patients it has been argued, that these could be a direct consequence of the roles of thrombopoietin and *MPL* in the brain.<sup>42-45</sup> However, the high correlation between structural abnormalities in the brain and intracranial bleedings argues for a secondary effect of thrombocytopenia. Indeed, most of these structural abnormalities observed in our cohort have also been reported as a consequence of intracranial bleedings,<sup>46-48</sup> even strabismus and nystagmus.<sup>49</sup> This is further supported by the observation that higher incidences of ocular anomalies have also been described for other BMFS going along with thrombocytopenia (Fanconi anemia, dendritic cells) but not for those with normal platelet counts (Diamond Blackfan anemia, Shwachman Diamond syndrome).<sup>50</sup> Previous reports of other non-hematological abnormalities refer to CAMT patients with unreported or wild-type *MPL* genotype.<sup>14,51</sup> Our data suggests that the primary effects of *MPL* deficiency are restricted to the hematopoietic system - most of the non-hematopoietic symptoms seem to be secondary to the thrombocytopenia or bone marrow failure. For other symptoms, especially those observed only in single cases or in highly consanguineous families<sup>52</sup> we suppose that they emerged coincidentally.

Although CAMT is regarded to be a preleukemic syndrome in most of the recent reviews, only weak evidence for this assumption exists. One single patient with CAMT and confirmed *MPL* mutation has been reported to develop a pre-B acute lymphoblastic leukemia.<sup>41</sup> Increased accumulation of chromosomal aberrations, however, has been observed in our and previous studies.<sup>53</sup> The exhaustion of hematopoietic stem cells due to *MPL* deficiency may be the reason for both, the acquisition of pre-leukemic cellular alterations due to increased hematopoietic stress, but also for early development of aplastic anemia leading to death or replacement of the hematopoietic system by means of HSCT, thereby preventing the development of overt leukemia. The debate about CAMT-MPL as a preleukemic syndrome therefore might be of less relevance.

Genotype-phenotype correlations in CAMT-MPL have led us to our concept of CAMT I and II groups: a complete loss of *MPL* function results in persistently low platelet counts and a fast progression into pancytopenia in CAMT I patients whereas a residual function of the receptor leads to a milder course with a transient increase of platelet counts

in the first year of life in CAMT II patients.<sup>4,14,15</sup>

The data from the present study allow for additional conclusions of clinical relevance:

- the course of the disease is mainly determined by the type of mutation. The same *MPL* mutations lead to high similarities in the hematological courses of patients, even if they are from different families or different ethnical background (e.g., mild course in patients with c.391+5G>C).

- the time course of pancytopenia development for patients with same *MPL* mutations is more variable than the course of thrombocytopenia. This could be caused by accelerated exhaustion of hematopoietic progenitors due to frequent bleedings or infections in some patients.<sup>54</sup>

- all patients with mutations leading to a complete loss of function (CAMT I) had a similar course with constantly severe thrombocytopenia. Platelet counts at birth and in the further course never exceed 50. and all of them showed a transition to pancytopenia. A complete *MPL* deficiency is probable in patients showing signs of aplastic anemia in the first months of life.

- missense mutations predicted to allow a residual function of the *MPL* receptor lead to a more variable course of CAMT. The most severe phenotypes, comparable to CAMT I (severe thrombocytopenia, early development of aplasia), were observed in patients with mutations p.Leu169His and p.Trp154Arg. Milder phenotypes (late detection of thrombocytopenia and delayed development of aplasia) were observed in patients with mutations p.Asp295Tyr and p.Pro394Ser and missense mutations affecting the intracytoplasmic domain.

- milder phenotypes with late development of aplastic anemia (respectively none during the period of record) have also been observed in patients with splice site mutations allowing for a residual normal splicing,<sup>26,41</sup> namely c.391+5G>C and c.212+5G>A.

- patients with germ line *MPL* mutations and a late onset form of amegakaryocytic thrombocytopenia or aplastic anemia (e.g., patients CAMT058, CAMT101, CAMT102 with moderate thrombocytopenia detected at the age of >2 years) should be also regarded as CAMT-MPL. This includes the patients previously described as familial aplastic anemia.<sup>55</sup>

- there may exist a small subgroup of CAMT II patients without development of pancytopenia. For patients with new mutations predicted to have minor impact on function or with mutations previously detected in patients with a mild course (namely c.391+5G>C, c.212+5G>A, or p.Pro275Thr) it might be appropriate to wait for first signs of bone marrow failure before proceeding to HSCT, especially if no appropriate family donor is available.

- type and localization of *MPL* mutations are not predictive for pre- and perinatal intracranial hemorrhages. There are no differences in the frequency and severity of these

bleedings between patient groups CAMT I and CAMT II. The existence of a deleterious *MPL* mutation is a major risk factor for the occurrence of intracranial bleedings.

- structural and clinical non hematologic abnormalities in CAMT-MPL are not correlated with specific mutations.

- there is a small group of patients who present clinically as CAMT, but in whom a deleterious *MPL* mutation can only be detected in one allele. Possible explanations for the seeming inconsistency between genotype and phenotype include somatic mosaicism, deletions or changes in regulatory sequences that prevent the translation of a functional protein, or - rather unlikely especially in family cases - accidental coincidence.

- a further consideration for clinical presentation of CAMT-MPL is whether, in addition to existing *MPL* mutations, mutations or functional single nucleotide polymorphisms in other genes or epigenetic differences are involved in the observed phenotypic heterogeneity of CAMT-MPL.

Our analysis of a large cohort of CAMT-MPL patients demonstrates a higher variability of clinical courses than described so far. The diagnosis CAMT-MPL has to be considered even for those patients who are inconspicuous in the first months of life or show somatic anomalies typical for other BMFS. Since almost all CAMT-MPL patients inevitably develop a fatal bone marrow failure that requires treatment with HSCT, all children with unclear forms of hypomegakaryocytic thrombocytopenia should be tested for *MPL* mutations. If molecular confirmation of CAMT is not possible, at least those IBMFS should be excluded for which HSCT is not an option (e.g., thrombopoietin production defect) or which need another transplantation regimen (e.g., Fanconi anemia, Diamond Blackfan anemia).

### Disclosures

No conflicts of interest to disclose

### Contributions

MG and MB designed and performed research, analyzed data, and wrote the manuscript.

### Acknowledgments

The authors would like to thank all patients and their families who participated in this study. We are also grateful to the physicians who provided us with material and data from their patients. We would like to acknowledge the excellent technical assistance of Yvonne Peter and Christina Struckmann.

### Funding

This work was supported in part by grants from the Federal Ministry of Education and Research (German Network on Congenital Bone Marrow Failure Syndromes) and by the transnational ERA-NET funding European Platelet Network (EUPLANE).

## References

- Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. *Br J Haematol.* 2009;146(1):3-16.
- Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. *Semin Thromb Hemost.* 2011;37(6):673-681.
- Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. *Proc Natl Acad Sci U S A.* 1999;96(6):3132-3136.
- Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. *Blood.* 2001;97(1):139-146.
- Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. *Haematologica.* 2010;95(8):1236-1240.
- Dasouki MJ, Rafi SK, Olm-Shipman AJ, et al. Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. *Blood.* 2013;122(20):3440-3449.
- Seo A, Ben-Harosh M, Sirin M, et al. Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin. *Blood.* 2017;130(7):875-880.
- Pecci A, Ragab I, Bozzi V, et al. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim. *EMBO Mol Med.* 2018;10(1):63-75.
- Basel-Vanagaite L, Dokal I, Tamary H, et al. Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations. *Haematologica.* 2008;

- 93(6):943-944.
10. Giampietro PF, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. *Am J Med Genet.* 1997; 68(1):58-61.
  11. Germeshausen M, Ancliff P, Estrada J, et al. MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia. *Blood Adv.* 2018;2(6):586-596.
  12. Christensen RD, Wiedmeier SE, Yaish HM. A neonate with congenital amegakaryocytic thrombocytopenia associated with a chromosomal microdeletion at 21q22.11 including the gene RUNX1. *J Perinatol.* 2013;33(3):242-244.
  13. Geddis AE. Congenital amegakaryocytic thrombocytopenia. *Pediatr Blood Cancer.* 2011;57(2):199-203.
  14. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. *Br J Haematol.* 2005;131(5):636-644.
  15. Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. *Hum Mutat.* 2006;27(3):296.
  16. Stoddart MT, Connor P, Germeshausen M, Ballmaier M, Steward CG. Congenital amegakaryocytic thrombocytopenia (CAMT) presenting as severe pancytopenia in the first month of life. *Pediatr Blood Cancer.* 2013;60(9):E94-96.
  17. Ok Bozkaya I, Yarali N, Isik P, Unsal Sac R, Tavil B, Tunc B. Severe clinical course in a patient with congenital amegakaryocytic thrombocytopenia due to a missense mutation of the c-MPL gene. *Turk J Haematol.* 2015;32(2):172-174.
  18. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics.* 2015;31(16):2745-2747.
  19. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* 2009;4(7):1073-1081.
  20. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010;7(4):248-249.
  21. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods.* 2014;11(4):361-362.
  22. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. *J Comput Biol.* 1997;4(3):311-323.
  23. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol.* 2004;11(2-3):377-394.
  24. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res.* 2009;37(9):e67.
  25. Ballmaier M, Holter W, Germeshausen M. Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias. *Haematologica.* 2015;100(9):e341-344.
  26. Gandhi MJ, Pendergrass TW, Cummings CC, Ihara K, Blau CA, Drachman JG. Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation. *Exp Hematol.* 2005;33(10):1215-1221.
  27. Varghese LN, Zhang JG, Young SN, et al. Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia. *Growth Factors.* 2014;32(1):18-26.
  28. Jalas C, Anderson SL, Laufer T, et al. A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. *Blood Cells Mol Dis.* 2011;47(1):79-83.
  29. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. *Hematology Am Soc Hematol Educ Program.* 2007;2007:29-39.
  30. Steele M, Hitzler J, Doyle JJ, et al. Reduced intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in a patient with congenital amegakaryocytic thrombocytopenia and monosomy 7. *Pediatr Blood Cancer.* 2005;45(2):212-216.
  31. Tuller T, Waldman YY, Kupiec M, Ruppin E. Translation efficiency is determined by both codon bias and folding energy. *Proc Natl Acad Sci U S A.* 2010;107(8):3645-3650.
  32. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. *Blood Rev.* 2008;22(3):141-153.
  33. Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. *Am J Clin Pathol.* 2013;139(1):9-29.
  34. Rivers A, Slayton WB. Congenital cytopenias and bone marrow failure syndromes. *Semin Perinatol.* 2009;33(1):20-28.
  35. Geddis AE. Inherited thrombocytopenia: Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. *Semin Hematol.* 2006;43(3):196-203.
  36. Sola-Visner M. Platelets in the neonatal period: developmental differences in platelet production, function, and hemostasis and the potential impact of therapies. *Hematology Am Soc Hematol Educ Program.* 2012;2012:506-511.
  37. Lorenz V, Ramsey H, Liu ZJ, et al. Developmental stage-specific manifestations of absent TPO/c-MPL signalling in newborn mice. *Thromb Haemost.* 2017;117(12):2322-2333.
  38. Baker-Groberg SM, Lattimore S, Recht M, McCarty OJ, Haley KM. Assessment of neonatal platelet adhesion, activation, and aggregation. *J Thromb Haemost.* 2016;14(4):815-827.
  39. Bunting S, Widmer R, Lipari T, et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. *Blood.* 1997;90(9):3423-3429.
  40. Ballmaier M, Germeshausen M, Krukemeier S, Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. *Ann N Y Acad Sci.* 2003;996:17-25.
  41. Steinberg O, Gilad G, Dgany O, et al. Congenital amegakaryocytic thrombocytopenia-3 novel c-MPL mutations and their phenotypic correlations. *J Pediatr Hematol Oncol.* 2007;29(12):822-825.
  42. Dame C, Wolber EM, Freitag P, Hofmann D, Bartmann P, Fandrey J. Thrombopoietin gene expression in the developing human central nervous system. *Brain Res Dev Brain Res.* 2003;143(2):217-223.
  43. Ehrenreich H, Hasselblatt M, Knerlich F, et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. *Proc Natl Acad Sci U S A.* 2005;102(3):862-867.
  44. Ivanova A, Wuerfel J, Zhang J, Hoffmann O, Ballmaier M, Dame C. Expression pattern of the thrombopoietin receptor (Mpl) in the murine central nervous system. *BMC Dev Biol.* 2010;10:77.
  45. Hoffmann O, Rung O, Im AR, et al. Thrombopoietin Contributes to Neuronal Damage in Experimental Bacterial Meningitis. *Infect Immun.* 2011;79(2):928-936.
  46. Castro Conde JR, Martinez ED, Rodriguez RC, Rodriguez De Hoyos AL. CNS siderosis and dandy-walker variant after neonatal alloimmune thrombocytopenia. *Pediatr Neurol.* 2005;32(5):346-349.
  47. Goto T, Kakita H, Takasu M, et al. A rare case of fetal extensive intracranial hemorrhage and whole-cerebral hypoplasia due to latent maternal vitamin K deficiency. *J Neonatal Perinatal Med.* 2018;11(2):191-194.
  48. Marszal E, Jamroz E, Pilch J, Kluczevska E, Jablęcka-Deja H, Krawczyk R. Agenesis of corpus callosum: clinical description and etiology. *J Child Neurol.* 2000;15(6):401-405.
  49. O'Keefe M, Kafil-Hussain N, Flitcroft I, Lanigan B. Ocular significance of intraventricular haemorrhage in premature infants. *Br J Ophthalmol.* 2001;85(3):357-359.
  50. Tsilou ET, Giri N, Weinstein S, Mueller C, Savage SA, Alter BP. Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. *Ophthalmology.* 2010;117(3):615-622.
  51. Yildirim AT, Günes BT, Oymak Y, et al. Congenital amegakaryocytic thrombocytopenia: three case reports from patients with different clinical diagnoses and somatic abnormalities. *Blood Coagul Fibrinolysis.* 2015;26(3):337-341.
  52. Zlotogora J. What is the birth defect risk associated with consanguineous marriages? *Am J Med Genet.* 2002;109(1):70-71.
  53. Maserati E, Panarello C, Morerio C, et al. Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498). *Haematologica.* 2008;93(8):1271-1273.
  54. Matatall KA, Jeong M, Chen S, et al. Chronic infection depletes hematopoietic stem cells through stress-induced terminal differentiation. *Cell Rep.* 2016;17(10):2584-2595.
  55. Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. *Haematologica.* 2012;97(4):524-528.
  56. Savoia A, Dufour C, Locatelli F, et al. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. *Haematologica.* 2007;92(9):1186-1193.
  57. Kohler S, Carmody L, Vasilevsky N, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. *Nucleic Acids Res.* 2019;47(D1):D1018-D1027.